Gallbladder Cancer Pipeline and Clinical Trials Assessment (2023) | Companies – Celgene, MedImmune, Ohara Pharmaceuticals, and Others

Advertisements

DelveInsight’s report titled “Gallbladder Cancer Pipeline Insight, 2023” offers extensive information on more than 10 companies and over 10 pipeline drugs in the field of Gallbladder cancer research. The report encompasses detailed profiles of the pipeline drugs for Gallbladder cancer, including information on clinical trials and nonclinical stage products. It also provides a comprehensive assessment of the therapeutics based on product type, stage, route of administration, and molecule type. Additionally, the report highlights the inactive pipeline products in this domain.

 

For the emerging drugs in Gallbladder Cancer, the pipeline analysis report presents a comprehensive view of the therapeutic landscape, considering the development stage, product type, and route of administration, molecule type, and mechanism of action (MOA). The research on the Gallbladder Cancer pipeline covers various aspects such as business opportunities, challenges, potential partnerships, strong competitors, and growth strategies. It provides a detailed description of each drug, including its mechanism of action, clinical trial studies conducted for Gallbladder Cancer, any NDA approvals obtained for Gallbladder Cancer, and the product development activities encompassing technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant details.

 

To explore more information on the latest breakthroughs in the Gallbladder Cancer Pipeline treatment landscape of the report, click here @ Gallbladder Cancer Pipeline Outlook

 

Key Takeaways from the Gallbladder Cancer Pipeline Report

DelveInsight’s Gallbladder Cancer Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.
The leading Gallbladder Cancer Companies include Celgene, MedImmune, Ohara Pharmaceuticals, and others.
Promising Gallbladder Cancer Pipeline Therapies include M7824, Panitumumab, oxaliplatin, exatecan mesylate, ZD6474, Vandetanib, Gemcitabine, Capecitabine, Cisplatin, gemcitabine hydrochloride, and others.
The Gallbladder Cancer companies and academics are working to assess challenges and seek opportunities that could influence Gallbladder cancer R&D. The Gallbladder Cancer pipeline therapies under development are focused on novel approaches to treat/improve Gallbladder cancer.
Celgene’ new drug candidate, Durvalumab, is human immunoglobulin G1 kappa monoclonal antibody that is in development for the treatment of Gallbladder cancers. It inhibits the immune response by blocking the interaction of PD-L1 with PD 1 and CD80. The drug has demonstrated good efficacy and safety results in its phase I clinical trials.
Ohara Pharmaceutical’s “breakthrough” drug ONC 201 is a small orally administered molecule in development for the treatment of Gallbladder cancer. The drug inactivates the Akt/ERK signaling, leading to upregulation of the proapoptotic immune cytokine TRAIL.

 

Gallbladder Cancer Overview

Gallbladder cancer is a small, pear-shaped organ situated beneath the liver, responsible for storing bile enzymes and aiding in digestion. It is an uncommon form of cancer characterized by the abnormal growth of cells in the area of the gallbladder. The majority of gallbladder cancer cases originate from glandular cells that make up the inner lining of the organ.

 

For further information, refer to the detailed Gallbladder Cancer Unmet Needs, Gallbladder Cancer Market Drivers, and Gallbladder Cancer Market Barriers, click here for Gallbladder Cancer Ongoing Clinical Trial Analysis

 

Gallbladder Cancer Emerging Drugs Profile

Durvalumab: Celgne
ONC 201: Ohara Pharmaceuticals

 

Gallbladder Cancer Pipeline Therapeutics Assessment

There are approx. 10+ Gallbladder Cancer companies are developing Gallbladder Cancer therapies. The companies which have their Gallbladder cancer drug candidates in the most advanced stage, i.e. phase II include, Celgene.

 

Request a sample and discover the recent advances in Gallbladder Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Gallbladder Cancer Treatment Landscape

 

Gallbladder Cancer Pipeline Therapeutics Assessment

• Gallbladder Cancer Assessment by Product Type

• Gallbladder Cancer by Stage and Product Type

• Gallbladder Cancer Assessment by Route of Administration

• Gallbladder Cancer by Stage and Route of Administration

• Gallbladder Cancer Assessment by Molecule Type

• Gallbladder Cancer by Stage and Molecule Type

 

Some of the Companies in the Gallbladder Cancer Therapeutics Market include-

Celgene, MedImmune, Ohara Pharmaceuticals, INSYS Therapeutics Inc, Merck, Eli Lilly, and Company, EMD Serono, and Others.

 

Dive deep into rich insights for drugs for Gallbladder Cancer Pipeline, click here @ Gallbladder Cancer Unmet Needs and Analyst Views

 

Scope of the Gallbladder Cancer Pipeline Report

Coverage- Global
Gallbladder Cancer Companies- Celgene, MedImmune, Ohara Pharmaceuticals, INSYS Therapeutics Inc, Merck, Eli Lilly and Company, EMD Serono, and Others
Gallbladder Cancer Pipeline Therapies- cisplatin, gemcitabine hydrochloride, M7824, Gemcitabine, CTX-009, Paclitaxel, Fentanyl sublingual spray, and others
Gallbladder Cancer Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Gallbladder Cancer Mergers and acquisitions, Gallbladder Cancer Licensing Activities @ Gallbladder Cancer Emerging Drugs, and Recent Trends

 

Table of Content

Introduction
Gallbladder Cancer Executive Summary
Gallbladder cancer: Overview
Gallbladder cancer Pipeline Therapeutics
Gallbladder cancer Therapeutic Assessment
Gallbladder cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Gallbladder cancer Collaboration Deals
Mid Stage Products (Phase II)
Durvalumab : Celgene
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ONC 201: Ohara Pharmaceuticals
Drug profiles in the detailed report…..
Inactive Products
Gallbladder cancer Key Companies
Gallbladder cancer Key Products
Gallbladder cancer- Unmet Needs
Gallbladder cancer- Market Drivers and Barriers
Gallbladder cancer- Future Perspectives and Conclusion
Gallbladder cancer Analyst Views
Gallbladder cancer Key Companies
Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.

Advertisements

Smart public opinion research for everyone.

%d bloggers like this: